InMode beat Q2 earnings expectations by $0.02 per share and topped revenue estimates on steady U.S. demand for its RF microneedling and radiofrequency platforms. The company's core U.S. installed base continues to drive recurring revenue and procedure volume.
Devices & Tech
InMode Q2 Beats on Steady U.S. Device Demand
Earnings topped estimates; U.S. market holding despite competitive RF microneedling saturation.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
U.S. RF microneedling demand remains steady despite growing competitive saturation.
For practice owners, InMode's resilience reflects the durability of RF microneedling as a workhorse modality—high patient demand, strong per-treatment margins, and minimal reimbursement friction. However, the competitive field (Cutera, Lumenis, Candela) has densified, and device acquisition cost and break-even patient volume remain critical variables. If you're evaluating an RF platform acquisition or lease, benchmark InMode's installed-base economics against newer entrants offering lower capex or faster ROI.
Source: original report ↗
Frequently asked questions
Is RF microneedling still profitable for med spas in 2024?
Yes—InMode's Q2 earnings beat shows steady U.S. demand, high per-treatment margins, and minimal reimbursement friction. RF microneedling remains a workhorse modality with strong patient demand, though you'll need to benchmark device costs and break-even patient volume against competitors like Cutera, Lumenis, and Candela.
How many RF microneedling devices do I need to break even?
Break-even patient volume varies by device cost, treatment pricing, and local competition. InMode's installed-base economics show the company drives recurring revenue through procedure volume, but you should calculate your specific ROI based on your capex, lease terms, and target patient throughput before committing.
Should I buy InMode or lease it?
Evaluate both options against your cash flow and growth timeline. InMode's strong market position supports resale value if you buy, but leasing preserves capital and lets you upgrade faster if competitive RF platforms with lower capex or faster ROI emerge.
What's driving InMode's Q2 earnings beat?
Steady U.S. demand for RF microneedling and radiofrequency platforms, combined with a resilient installed base generating recurring revenue. InMode beat earnings estimates by $0.02 per share and topped revenue expectations despite competitive saturation in the RF microneedling market.
How competitive is the RF microneedling market right now?
The field has densified significantly, with major players including Cutera, Lumenis, and Candela competing alongside InMode. Device acquisition cost and break-even patient volume are now critical differentiators—newer entrants may offer lower capex or faster ROI, so compare total cost of ownership before purchasing.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.